1	Impact of Antibody Cocktail Therapy Combined with Casirivimab and
2	Imdevimab on Clinical Outcome for Covid-19 patients in A Real-Life Setting: A
3	Single Institute Analysis
4	
5	Yasutaka Kakinoki, Kazuki Yamada, Yoko Tanino, Keiko Suzuki, Takaya Ichikawa, Ai
6	Nakamura, Shin Kukita, Akito Uehara, Seisuke Saito, Shohei Kuroda, Hidemitsu
7	Sakagami, Yuuki Nagashima, Kae Takahashi, and Satoshi Suzuki
8	
9	Division of Internal Medicine, Asahikawa City Hospital, Asahikawa, Japan
10	
11	Corresponding author:
12	Yasutaka Kakinoki, MD, PhD.
13	Asahikawa City Hospital, 1-1-65, Kinseicho, Asahikawa, 070-8610, Japan
14	e-mail: <u>y_kakinoki@ach.hokkaido.jp</u>
15	
16	Shared co-first authorship: Dr. Yasutaka Kakinoki and Dr. Kazuki Yamada
17	contributed equally to this article.
18	
19	Keywords: Covid-19, SARS-CoV-2, cocktail, ronapreve, REGEN-COV
20	
21	
22	
23	
24	
25	NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

#### 26 ABSTRACT

Background. Recent data from clinical trial suggest that antibody cocktail therapy, a combination of the monoclonal antibodies casirivimab and imdevimab, has been shown to rapidly reduce the viral load and markedly decrease the risk of hospitalization or death among high-risk patients with coronavirus disease 2019 (Covid-19). However, it remains unclear how effective in a real-life clinical setting the therapy is.

32 Methods. We retrospectively analyzed mild to moderate Covid-19 patients with one or 33 more high-risk factors for severe disease who consecutively underwent the antibody 34 cocktail therapy of the disease in our institute in June 2021 through early September 35 2021, compared to those with high-risk factors who were isolated in non-medical 36 facilities consecutively during the same period, thereby being not given the antibody 37 cocktail therapy there. The key outcome was the percentage of patients with Covid-19-38 related deterioration which needed additional medical interventions, such as oxygen 39 support or other antiviral therapies.

40 **Results.** Data from 55 patients with initially receiving antibody cocktail therapy and 53 41 patients with isolation into non-medical facilities are analyzed. 22 (41.5 %) of 53 patients 42 with isolation facilities were finally hospitalized to receive medical interventions. On the 43 other hand, 13 (23.6 %) of 55 patients with antibody cocktail therapy in our hospital 44 subsequently underwent further medical interventions because of the progression. In 45 multivariate analysis with variables of age, BMI, and high-risk factors, the antibody 46 cocktail therapy significantly reduced 70 % in the need for further medical interventions 47 compared to the initial isolation in the non-medical facilities (odds ratio=0.30, 95%CI 48 [0.10-0.87], p=0.027). Furthermore, patients with 96% or above of SPO2 were 49 significantly more favorable for the therapy than those with 95% or below of SPO2.

50 Conclusion. The treatment of antibody cocktail was closely linked to reduction in the

51 need for further medical interventions. The result indicates that the antibody cocktail 52 therapy is associated with reducing the strain on hospitals, which is related to the 53 improvement of medical management for public health care in Covid-19 pandemic era.

54

#### 55 INTRODUCTION

56 Coronavirus disease 2019 (Covid-19), caused by severe acute respiratory syndrome 57 coronavirus 2 (SARS-CoV-2), was first detected in December 2019 and was declared a 58 global pandemic in March 2020 [1-3]. In Japan, as of September 22, approximately 1.68 59 million people have been infected and 17 thousand are dead, and about 55% people of 60 the population are fully vaccinated [4]. Although those records regarding infected figures 61 appear to be less than in Western countries, the several issues in hospitals are 62 challenging because of less enough hospital beds availability and shortages of hospital 63 staffs, mostly nurses. To resolve these issues, Japan's Ministry of Health, Labour and 64 Welfare (MHLW) has approved the antibody cocktail of casirivimab and imdevimab, 65 brand name of Ronapreve<sup>TM</sup> (provided from Roche globally, and from CHUGAI 66 Pharmaceutical in Japan), for the treatment of mild to moderate Covid-19 patients with 67 high-risk factors via intravenous infusion, which was granted a Special Approval 68 Pathway under article 14-3 of the Pharmaceuticals and Medical Devices Act on July 19 69 in 2021 [5]. The approval of the MHLW has based on results from the global phase 3 70 REGN-COV2067 trial [6] in high-risk non-hospitalized Covid-19 patients, which showed 71 that the cocktail therapy reduced hospitalization or any-caused death by 70% and Covid-72 19-related symptom duration by 4 days as well as a phase 1 clinical study with safety, 73 tolerability and pharmacokinetics in Japanese people [7]. In addition, the ability of the 74 cocktail to retain activity against emerging variants including delta variant has been 75 demonstrated in vitro study [8-10]. However, these results have been coming up from

randomized clinical trials and experimental studies, and therefore what is happening in
a daily clinical practice on the cocktail therapy remains to be seen. Here, we describe
clinical benefits of Ronapreve coming from a real-life clinical practice in our institute.

79

80 METHODS

81 PATIENTS

82 Eligible patients were 20 years of age or older, with a confirmed SARS-CoV-2 infection 83 by real-time reverse transcription PCR (RT-PCR) test, a Covid-19-related fever ( $\geq$ 84 37.5°C) in mild to moderate condition, and presence of risk factors meeting the criteria 85 for severe Covid-19 [6] during June 2021 through early September 2021. Local public 86 health centers made allocation decisions based on factors such as severity and urgency 87 to deliver patients to hospitals or non-medical facilities for isolation. The use of patient's 88 clinical information was approved by the Research Ethics Committee of Asahikawa City 89 Hospital which oversaw the study conduct and documentation, and the data available 90 from non-medical facilities were authorized to be provided with fully anonymous 91 condition by the chief officer of the local public health center. This study was conducted 92 in accordance with the principles of the Declaration of Helsinki.

#### 93 MEDICAL INTERVENTION

94 Patients assigned to our institute were firstly reviewed to be applicable for the use of 95 ronapreve according to the criteria [6]. Ronapreve was given at equal doses of 600mg of 96 casirivimab and imdevimab combined in a 100ml normal saline solution through 97 intravenous infusion over 30 minutes, if applicable (ronapreve group). Afterward, if 98 necessary, patients can receive additional further therapy such as oxygen support, 99 steroids, or antiviral drugs. Patients assigned to non-medical facilities were under watch 100 and wait situation to see if they progress to the point they need hospitalization (watchful

101 observation group). When patients possibly progress or got progressed, they were 102 immediately transferred to hospitals to receive some treatments for Covid-19.

## 103 KEY and OTHER OUTCOMES

104 Key outcomes were designated to the difference between ronapreve and watchful 105 observation groups in terms of the necessity of additional further treatment such as 106 oxygen support or antiviral drugs. In ronapreve group, the addition of further treatment 107 after ronapreve administration indicated the failure of the cocktail therapy as a 108 definition. In watchful observation group, the transfer of patients to hospitals to receive 109 some therapies indicated that patients were under intractable or deteriorating 110 conditions. Other outcomes were designated in ronapreve group to investigate the 111 duration of fever and adverse events after ronapreve administration.

## 112 STATISTICAL ANALYSIS

113 Logistic regression models for multivariate analysis were applied to evaluate the 114 proposed significant factors in terms of the efficacy of ronapreve, using age, BMI, high-115 risk factors, and Percutaneous oxygen saturation (SPO2) as explanatory variables. 116 Receiver Operating Characteristic (ROC) curves were used to determine the cut-off value 117 for SPO2. All p-values were two sided and P-values of 0.05 or less were considered 118 statistically significant. All statistical analyses were performed with EZR version1.50 119 (Saitama Medical Center, Jichi Medical University, Saitama, Japan), which is a 120 graphical user interface for R (The R Foundation for Statistical Computing, Vienna, 121 Austria). More precisely, it is a modified version of R commander designed to add 122 statistical functions frequently used in biostatistics [11].

123

124 **RESULTS** 

#### 125 PATIENT'S CHARACTERISTICS

Patients were collected consecutively during the period from June 2021 through early September 2021, when the delta variants were widely spreading in our community. As a result, 55 patients were given Ronapreve first in our institute (ronapreve group) and 53 patients were initially assigned to non-medical isolation facilities to see the situations watchfully (watchful observation group) (Table 1).

131 In ronapreve group, the median age was 51 years, 69.1% were male, and median BMI 132 score was 27.5. In proportion of the number patients have in high-risk factors, 30.9% 133 possessed 1 factor, 32.7% 2 factors, and 36.4% 3 or more factors. SPO2 tests revealed 134 67.3% of patients to be 96% or above and 43.6% of patients have pneumonia detected by 135 CT scan, X-ray imaging, or stethoscopic findings. In contrast, in watchful observation 136 group, although distributions of age and gender were similar, proportion of high-risk 137 factors and BMI scores regarding disease progression were significantly lower (p<0.001 138 and p=0.01, respectively), compared to ronapreve group. Details of the high-risk factors 139 patients have in both groups together are provided in the Supporting Information (Table 140 S1).

## 141 CLINICAL EFFICACY

## 142 Key outcomes

143 In ronapreve group, 23.6% (13/55) of patients eventually needed further medical 144 interventions after ronapreve administration, such as oxygen support or antiviral drugs 145 (Figure 1). However, no deterioration was found beyond 5 days after ronapreve 146 administration, meaning the remaining 76.4% (42/55) of patients in this group fully 147 recovered from Covid-19 (Figure 1A). On the other hand, Patients in watchful 148 observation group showed that those who got progressive were increasingly transferred 149 to hospitals until 12 days after the disease onset, finally mounting up to 41.5% (22/53) of 150 patients (Figure 1B). In multivariate analysis with age, BMI, and high-risk factors as

explanatory variables, ronapreve significantly reduced the need for additional treatments by 70% compared to watchful observation group patients (odds ratio=0.301, 95%CI [0.104-0.869], p=0.026) (Figure 2). Furthermore, in ronapreve group, patients with 96% or above of SPO2, the cutoff value was established by ROC curves, showed 97% reduction significantly on the additional treatment compared to patients with 95% or below of SPO2 (odds ratio=0.03, 95%CI [0.01-0.22], p<0.001) (Figure 3).

## 157 **Other outcomes**

158 Ronapreve was started at a median time of 3 days from the onset (range; 0 - 7 days) 159 (Figure S1). Ronapreve treatment was associated with quick relief from Covid-19-160 related fever. Out of 27 in-patients, 14 patients (51.9%) were reduced from fever until 161 the next day, and all 27 patients has achieved afebrile state until 4 days from the 162 administration, though this result came from limited numbers of 27 in-patients because 163 of missing data from other 28 out-patients (Figure 4). In regard to vaccinated patients 164 enrolled, in 3 with one shot and in 5 with 2 shots, one and 4 patients showed to be related 165 to the fever-down, respectively (Table S2). In aspect of adverse events, one patient 166 showed infusion reaction of mild swelling of eyelids and urticaria of upper arms during 167 the drip of ronapreve, resulting in stopping on the way, and 2 patients showed skin 168 eruption around 2-3 hours after the administration (Table S3).

169

#### 170 **DISCUSSION**

Ronapreve (also known as REGEN-COV in clinical trials) is a cocktail made up of two noncompeting neutralizing human IgG1 monoclonal antibodies, casirivimab and imdevimab, that target the receptor-binding domain of the SARS-CoV-2 spike protein, thereby preventing viral entry into human cells through the angiotensin-converting enzyme 2 (ACE2) receptor [8,12]. This cocktail therapy retains neutralization potency

against circulating SARS-CoV-2 variants of concern, including B.1.1.7 (or alpha), B.1.351

177 (or beta), B.1.617.2 (or delta) and so forth in vitro and in vivo [8-10].

178 In a real-life practice setting, we described that the administration of ronapreve 179 predicted 70% reduction in turning into additional treatment, as compared with watchful 180 observation in isolation facilities where patients are under watch and wait situation to 181 see if they progress to the point they need hospitalization to receive treatments (Figure 182 2). Moreover, we showed 97% reduction of additional treatments in those patients who 183 were given under conditions of 96% or above of SPO2, compared to those with 95% or 184 below (Figure 3). This result may be associated with suppression of SARS-CoV-2 itself 185 by ronapreve before a surge of inflammation in lungs. In addition, ronapreve was related 186 to substantially speed up recovery from Covid-19-related fever at a median time of just 187 1 day from the administration (Figure 4), which probably represents an additional 188 benefit for Covid-19 patients. It is worth noting that patients in ronapreve group were 189 under the worse conditions than those in watchful observation group in terms of risk 190 factors for the disease progression.

Our data in a real-life setting suggest that ronapreve has the potential to prevent mild to moderate Covid-19 patients with high-risk factors from receiving additional treatments, such as supplemental oxygen, dexamethasone, or antiviral therapies because of disease progression, which should be exclusively manipulated in hospital in Japan. This result indicates that ronapreve is associated with reducing the burden of the need to take care of Covid-19 patients in hospital beds, which is related to retaining public health care resources to be normal.

Overall, our findings described above are well consistent with data from previous clinical trials regarding ronapreve. The phase 1/2 trial data showed that REGEN-COV for Covid-19 patients lowered viral load, reduced the need for medical attention, and was highly

201 suggestive of a reduced risk for hospitalization [13]. The phase 3 clinical trial confirmed 202 that early treatment with REGEN-COV in outpatients with high-risk factors for severe 203 Covid-19 dramatically reduced the risk of hospitalization or all-cause death by 70.4% 204 and the symptom duration by 4 days at equal doses of 600mg of casirivimab and 205 imdevimab [6]. In addition, the phase 3 trial for the prevention of Covid-19 in household 206 contacts of infected individuals showed that subcutaneous administration of REGEN-207 COV reduced the risk of symptomatic Covid-19 infections by 81.4% [14]. These findings 208 suggest that REGEN-COV therapy in outpatients with Covid-19 has the potential to 209 improve patient outcomes and substantially reduce the health care burden by lowering 210 morbidity and mortality.

The important point for ronapreve treatment we mentioned above is that the efficacy for patients is diminished under the condition of 95% or below of SPO2. Since low SPO2 or pneumonia is probably associated with cytokine-storm-induced hyper-inflammation caused by SARS-CoV-2, steroid such as dexamethasone will be more effective to suppress the storm rather than ronapreve, because the antibody treatment probably affects the virus itself.

In conclusion, ronapreve, also known as REGEN-COV, is thought to be closely linked to reduction in the risk of hospitalization or the need for additional treatment, along with a potential benefit of prompt recovery from Covid-19-related fever. Although our data provided from a daily practice is small-sized and limited, the antibody cocktail therapy in early phase of the disease suggests a promising way to minimize the serious impact of Covid-19 on the public health care system.

223

224 **FINANCIAL DISCLOSURE:** I have no financial support or conflicts of interest.

226	ACKNOWLEGEMENT: The authors thank all the participating physicians and co-
227	medical staffs for their care of patients with Covid-19.
228	
229	SUPPORTING INFORMATION: Additional supporting information may be found
230	online in the Supporting Information section at the end of the article.
231	
232	
233	
234	
235	
236	
237	
238	
239	
240	
241	
242	
243	
244	
245	
246	
247	
248	
249	

### 250 **REFERENCES**

- 251 1. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia
- 252 in China, 2019. N Engl J Med 2020; 382: 727-733.
- 253 2. World Health Organization. WHO Director-General's opening remarks at the media
- briefing on COVID-19 11 March 2020. 2020 (https://www.who.int/director-
- 255 general/speeches/detail/who-director-general-s-opening-remarks-at-the-mrdia-
- 256 <u>briefing-on-covid-19---11-march-2020</u>).
- 3. Wu F, Zhao S, Yu B, et al. A new coronavirus associated with human respiratory
  disease in China. Nature 2020; 579: 265-269.
- 4. Ministry of Health, Labour and Welfare. Current status of the novel coronavirus
  infection and the response of the MHLW. 2020. Available at:
  <a href="https://www.mhlw.ga.jp/stf/newpage12312.html">https://www.mhlw.ga.jp/stf/newpage12312.html</a>. Accessed 22 September 2021.
- Ministry of Health, Labour and Welfare. Approval for Ronapreve<sup>™</sup> (casirivimab and imdevimab) for the treatment of patients with mild to moderate Covid-19.
  Available at: <u>https://www.mhlw.ga.jp/stf/newpage 19940.html</u>. Accessed 20 July 2021.
- 6. Weinreich DM, Sivapalasingam S, Norton T, et al. REGEN-COV antibody cocktail
  clinical outcomes study in Covid-19 outpatients. June 6, 2021
  (https://www.medrxiv.org/content/10.1101/2021.05.19.21257469v2). preprint.
- 269 7. Regeneron's COVID-19 outpatient trial prospectively demonstrates that REGN-
- 270 COV2 antibody cocktail significantly reduced virus levels and need for further
- 271 medical attention. Regeneron, October 28, 2020
- 272 (https://investor.regeneron.com/news-releases/news-release-details/regenerons-
- 273 <u>covid-19-outpatient-trial-prospectively-demonstrates</u>).
- 8. Baum A, Fulton BO, Wloga E, et al. Antibody cocktail to SARS-CoV-2 spike protein

prevents rapid mutational escape seen with individual antibodies. Science 2020; 369:
1014-1018.

- 277 9. Copin R, Baum A, Wloga E, et al. The monoclonal antibody combination REGEN-
- 278 COV protects against SARS-COV-2 mutational escape in preclinical and human
  279 studies. Cell 2021 June 5 (Epub ahead of print).
- 10. Wang P, Nair MS, Liu L, et al. Antibody resistance of SARS-CoV-2 variants B.1.351
  and B.1.1.7. Nature 2021; 593: 130-135.
- 282 11. Kanda Y. Investigation of the freely-available easy-to-use software"EZR" (Easy R)
- for medical statistics. Bone Marrow Transplant. 2013: 48, 452-458. advance online
- 284 publication 3 December 2012; doi: 10.1038/bmt.2012.244.
- 12. Hansen J, Baum A, Pascal KE, et al. Studies in humanized mice and convalescent
  humans yield a SARS-CoV-2 antibody cocktail. Science 2020; 369: 1010-1014.
- 287 13. Weinreich DM, Sivapalasingam S, Norton T, et al. REGN-COV2, a neutralizing
- antibody cocktail, in outpatients with Covid-19. N Engl J Med 2021; 384: 238-251.
- 289 14. O'Brien MP, Forleo-Neto E, Musser BJ, et al. Subcutaneous REGEN-COV antibody
- 290 combination to prevent Covid-19. N Engl J Med 2021 August 4 (Epub ahead of print).

291

292

- 294
- 295
- 296
- 297
- 298
- 299

## 300 Legends for Tables and Figures

301

302	Table	1.

- 303 Patients' Demographic and Epidemiological Characteristics.
- 304 Abbreviations: IQR, interquartile range; BMI, body mass index; SPO2, Percutaneous
- 305 oxygen saturation.
- 306 #High-risk factors for severe Covid-19 include an age of more than 50 years, obesity (BMI
- $307 \geq 30$ ), cardiovascular disease (including hypertension), chronic lung disease (including
- 308 asthma), chronic metabolic disease (including diabetes), chronic kidney disease
- 309 (including receipt of dialysis), chronic liver disease, and immunocompromise.

310

# 311 Figure 1.

- 312 Time to additional treatment.
- 313 Event indicates that additional treatments are started.
- 314 A) shows time (day) to the next additional treatment after ronapreve administration
- 315 (date of the dripping indicates day 0). B) shows time (day) to be hospitalized to receive
- 316 medical interventions from disease onset.

317

#### 318 Figure 2.

- 319 Multivariate analysis for the efficacy of ronapreve using variables of age, BMI, and high-
- 320 risk factors. Forest plots depict the comparison of the incidences between watchful
- 321 observation and ronapreve groups.

- 323 Figure 3.
- 324 Multivariate analysis for age  $\geq$  50 years, 1, or 2, or 3 or more high-risk factors, BMI  $\geq$  30,

and  $\text{SPO2} \ge 96\%$  in ronapreve group. Forest plots depict the comparison of the incidences.

- 327 **Figure 4.**
- 328 Accumulation of patinets with events from ronapreve administration (date of the
- 329 dripping indicates day 0).
- 330 Event indicates that fever is down.


haracteristics	Ronapreve (n=55)	W atchfulobservation $(n=53)$	p valu
edian age (IQR),yr	51.0 (20.0,94.0)	52.0 (20.0,68.0)	0.939
ale sex,no. % )	38 (69.1)	30 (56.6)	0.232
edian BMI (IQR)	27.5 (17.2,47.5)	23.5 (14.7, 38.6)	0.011
utients with high-risk factors, no. (%)			< 0.00
1 factor	17 (30.9)	41 (77.4)	
2 factors	18 (32.7)	6 (11.3)	
3 orm ore factors	20 (36.49	6 (11.39	
202,no. (%)			0.169
≧96%	37 (67.3)	28 (52.8)	
$\leq 95\%$	18 (32.7)	25 (47.2)	
neum onia, no. (%)			
ye s	24 (43.6)	N.E	
no	31 (56.4)	N .E	

|\_

1.


A) Ronapreve Group


**B) Watchful observation Group** 



n: 55 47 46 46 44 42 42 42 42 42 42 42 42 42 42 42

n: 53 53 53 52 50 49 40 37 35 34 33 32 31 31 31 31 3





ıre 4.

